Bionote USA attended the Western Veterinary Conference to be held March 6th to March 9th, 2022 at the Mandalay Bay Convention Center in Las Vegas, Nevada.WVC’s Annual Conference is one of the largest, most influential gatherings of veterinary professionals in the world. Bionote USA communicated with veterinary workers and vets who attended the conference through participation in the booth about how Vcheck could develop and help veterinary medicine. On this day, renowned Dr. Rozanski sponsored by Bionote, spoke about the role of NT-proBNP in clinical decision making and the benefits of point-of-care testing. NT-proBNP is correlated with heart size and systolic function, suggesting that the concentrations can be used to detect dogs with early disease. In addition, Vcheck Canine NT-proBNP is an in vitro diagnostic test kit for the quantitative measurement of NT-proBNP concentration in canine serum. This test kit precisely quantifies the degree of elevation in NT-proBNP levels in dogs. The ability to distinguish cardiac from non-cardiac causes of respiratory signs is important for further decisions on diagnostics and therapy. NT-proBNP allows distinguishing cardiac from respiratory disease in dogs with dyspnea. Also, this marker helps to detect dogs with Myxomatous Mitral Valve Degeneration (MMVD), which is the most common heart disease in dogs. In dogs with stable Congestive Heart Failure (CHF) due to MMVD, NT-proBNP is of value in monitoring the effectiveness of medical treatment for CHF. In large breeds, Dilated Cardiomyopathy (DCM) is the most common cause of heart disease. Annual screening tests are recommended to determine if DCM is present even if dogs at elevated risk are healthy. The measurement of NT-proBNP increases the diagnostic accuracy with Holter monitoring (91% accuracy). Vcheck Canine NT-proBNP: The one-step test procedure is easy to follow and provides fast results within 15 minutes using serum samples from dogs. Bionote USA completed the 2022 Western Veterinary Conference, and in addition, Bionote KOREA and Bionote CHINA also plan to hold various external activities and conferences.
BIONOTE won the prize of "National Tax Tower of 100 billion" on March 3 in recognition of its contribution to national finances as an exemplary taxpayer on the occasion of the 56th Taxpayer's Day. The National Tax Tower of 100 billion is a monument in the name of the president, awarded to a high-value tax corporation with an annual total of more than 100 billion in corporate tax and special rural taxes voluntarily reported and paid by corporations since 2004. Bionote was awarded this time in recognition of its sincere tax payment, contribution to the community, and active contribution to society such as ethical business operation. Bionote CEO Cho Byung-ki said, "It is meaningful to contribute to the creation of a sincere tax culture, contributes to the healthy coexistence of people and animals, and will continue to contribute to the development of national finances through transparent management."
The Korea Animal Health Product Association (KAHPA) announced that In 2021, Bionote was awarded a commendation from the Minister of Agriculture, Food and Rural Affairs for its contribution to the development of the animal medicine industry. BIONOTE Co., Ltd., founded in 2003, is a manufacturer of diagnostic kits and equipment for animal diseases and is equipped with a wide product portfolio, from initial screening tests to molecular diagnosis. In 2019, BIONOTE USA was established, laying the groundwork for the company’s entry into the US market. Based on this, it is expanding its operations in overseas regions such as the United States, Europe, and Latin America, and in 2021, sales of animal products grew 45% year-on-year. A Bionote official said, "We plan to release Vcheck M and biochemical diagnostic test Vcheck C, which can be performed at the site this year." Also, Bionote said, "By presenting a new paradigm for diagnostic tests exclusively for numbers, we will once again gain momentum to achieve great growth."